Matteo Bassetti
Matteo Bassetti is an expert in Infectiology at Ospedale Policlinico San Martino (Italy). As of October 2026, ScienceLeadR ranks Matteo Bassetti in the top 1% of experts worldwide for Mycoses, Pneumonia and Coronavirus Infections. Matteo Bassetti has authored 1,010 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 4 of them ongoing. SLR score: 4,032 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Critical Care - Public Health - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 1010
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| A network between infectious diseases department and general practitioners for COVID-19 patients: towards a strengthened link? PMID 41439416 — anti-infective agents, general practitioners, drug therapy, covid-19, therapeutics, communicable diseases | J Chemother | 2025 | 0 |
| Severe strongyloidiasis and Gram-negative bacterial superinfections: epidemiology, clinical implications, and therapeutic strategies. PMID 42859848 — ivermectin, mortality, epidemiology, superinfection, adrenal cortex hormones, meningitis, sepsis, strongyloidiasis, transplants, therapeutics, neglected diseases, communicable diseases, infections | Curr Opin Infect Dis | 2026 | 0 |
| Source Control in Pseudomonas aeruginosa Bloodstream Infections: An Overlooked Pillar in Reducing 30-Day All-Cause Mortality. PMID 42787356 — mortality, pseudomonas, pseudomonas aeruginosa, sepsis, therapeutics, infections | Open Forum Infect Dis | 2026 | 0 |
| Machine learning to differentiate colonization from infection in multidrug-resistant Gram-negative bacteria: implications for further research. PMID 42731110 — gram-negative bacteria, antimicrobial stewardship, machine learning, research, therapeutics, learning, artificial intelligence, bacteria, communicable diseases, infections | Curr Opin Infect Dis | 2026 | 0 |
| Andes Virus: From Transmission Dynamics to Pandemic Potential. PMID 42690165 — public health, orthohantavirus, viruses, pandemics | Eur J Clin Invest | 2026 | 0 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 47
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections 2024-516216-16-00 — safety, cohort studies, aspergillus, fungi, mucorales, therapeutics, infections, fusarium | Phase 3 | Recruiting | 2026 |
| Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation the PRECISION double blind randomized clinical trial 2023-508123-12-00 — safety, signs and symptoms, immune system, therapeutics | Phase 2/Phase 3 | Not yet recruiting | 2023 |
| PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin resistant Enterobacteriaceae a non inferiority randomized controlled trial (PETERPEN) 2024-518583-13-00 — bacteremia, piperacillin, tazobactam drug combination, piperacillin, tazobactam, sepsis, meropenem, cephalosporins, therapeutics, enterobacteriaceae, infections | Phase 4 | Recruiting | 2025 |
| Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome NCT05926505 — safety, syringes, signs and symptoms, covid-19, immune system, receptors, interleukin-1, interleukin-1, interleukin 1 receptor antagonist protein, therapeutics, post-acute covid-19 syndrome | Phase 2/Phase 3 | Recruiting | 2023 |
LeadR Networks
Main global connection map